Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 217Other hematologic neoplasm 49Sarcoma 13Plasma cell 5Myeloid 4Dermatologic 4CNS 3Genitourinary 2Classical hematology 1

Conditions

Neuroblastoma 51Central Nervous System Neoplasms 43Medulloblastoma 22Brain Neoplasms 20Astrocytoma 15Oligodendroglioma 14Rhabdoid Tumor 7Choroid Plexus Neoplasms 7Neoplasms 6Glioma 6Optic Nerve Glioma 5Ganglioneuroblastoma 5Spinal Cord Neoplasms 4Sarcoma 4Neuroectodermal Tumors, Primitive 4Glioblastoma 4Sarcoma, Ewing 3Rhabdomyosarcoma 3Recurrence 3Lymphoma 3Gliosarcoma 3Ependymoma 3Wilms Tumor 2Pinealoma 2Neurofibromatosis 1 2Familial ependymoma 2Untreated Childhood Medulloblastoma 1Retinoblastoma 1Pyloric Stenosis, Hypertrophic 1Ototoxicity 1

Interventions

Filgrastim 11Temozolomide 9Melphalan 9Cyclophosphamide 9Radiotherapy 7Busulfan 7Magnetic Resonance Spectroscopy 6Rituximab 5Psychiatric Rehabilitation 5Methotrexate 5Etoposide 5Cytarabine 5Carboplatin 5sargramostim 4fludarabine 4etoposide phosphate 4Thiotepa 4Nivolumab 4Methylprednisolone 4Flow Cytometry 4Alemtuzumab 4Vincristine 3Topotecan 3Specimen Handling 3Peripheral Blood Stem Cell Transplantation 3Pemetrexed 3Granulocyte Colony-Stimulating Factor 3Early Intervention, Educational 3Drug Therapy 3Dexamethasone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma × Vincristine × CNS × Clear all
NCT01222780 2020-01-18

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

Acrotech Biopharma Inc.

Phase 1 Completed
22 enrolled
CNSGenitourinaryLymphoidOther hematologic neoplasmSarcoma

Brain Neoplasms, Leukemia, Lymphoma, Neoplasms, Wilms Tumor, Neuroblastoma, Sarcoma, Hematologic Neoplasms

NCT01735747 2013-03-12

Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma

Shandong Cancer Hospital and Institute

Phase 2 Unknown
16 enrolled
CNSLymphoid

Lymphoma, Central Nervous System Neoplasms

NCT00734773 2012-05-18

Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL

Northwestern University

Phase EARLY_PHASE1 Withdrawn
CNSLymphoid

Lymphoma, Central Nervous System Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡